LOC728379 Activators encompass a spectrum of chemical compounds that indirectly stimulate the functional activity of the deubiquitinating enzyme LOC728379 through diverse signaling pathways. Forskolin, by increasing cAMP concentrations, indirectly influences LOC728379 by activating PKA, which can impact proteins that modulate LOC728379's activity. Similarly, PMA, by activating PKC, could lead to phosphorylation of proteins that interact with LOC728379, potentially enhancing its deubiquitination function. Ionomycin raises intracellular Ca2+ levels, which could activate calcium-dependent proteases and protein interactions, indirectly affecting LOC728379 activity. LY294002 and U0126, by inhibiting PI3K and MEK1/2 respectively, modulate pathways that could shift cellular proteostasis and indirectly augment the functional activity ofLOC728379. Additionally, Epigallocatechin gallate (EGCG), acting as a tyrosine kinase inhibitor, may reduce competitive signaling, possibly leading to an enhanced role for LOC728379 in protein stability regulation.
LOC728379's activity is further influenced by compounds that affect various cellular signaling processes. MG132, by inhibiting the proteasome, could increase the pool of ubiquitinated proteins, potentially raising the functional demand for LOC728379's deubiquitinating activity. The nitric oxide donor, S-Nitroso-N-acetylpenicillamine (SNAP), may indirectly promote LOC728379's activity by affecting protein modification pathways. Okadaic acid's inhibition of protein phosphatases PP1 and PP2A could indirectly enhance LOC728379 activity by affecting the phosphorylation state of proteins that interact with it. Thapsigargin, by inhibiting SERCA pumps, increases cytosolic calcium levels, which may influence LOC728379 activity through calcium-dependent signaling pathways. Staurosporine, despite being a broad kinase inhibitor, might selectively activate pathways related to LOC728379 by altering the phosphorylation landscape. Lastly, 5-Azacytidine could lead to changes in gene expression that indirectly increase LOC728379 activity by affecting the cellular levels of interacting or regulatory proteins, highlighting a complex network of intracellular signals that collectively facilitate the enhancement of LOC728379's functional role in deubiquitination without the need for direct activation or upregulation of its expression.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $78.00 $270.00 | 80 | |
Ionomycin acts as a calcium ionophore, increasing intracellular calcium concentrations. This elevation in Ca2+ can activate calcium-dependent signaling pathways that may indirectly augment the functional activity of LOC728379 by altering the cellular context in which LOC728379 operates. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA is a potent activator of protein kinase C (PKC), which can lead to the phosphorylation of proteins that interact with LOC728379, potentially promoting its deubiquitination activity. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
EGCG is a tyrosine kinase inhibitor that may upregulate LOC728379 activity by reducing competitive signaling pathways, thereby indirectly enhancing the deubiquitination processes that LOC728379 could be involved in. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor that can modulate the PI3K/AKT/mTOR pathway, which may indirectly elevate the functional activity of LOC728379 by impacting signaling cascades that regulate protein stability and degradation. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is an inhibitor of MEK1/2, which can lead to the modulation of the MAPK/ERK pathway. This modulation may result in altered signaling dynamics that indirectly promote the activities of deubiquitinases such as LOC728379. | ||||||
(±)-S-Nitroso-N-acetylpenicillamine | 79032-48-7 | sc-200319B sc-200319 sc-200319A | 10 mg 20 mg 100 mg | $74.00 $114.00 $374.00 | 18 | |
SNAP is a nitric oxide donor that enhances nitric oxide (NO) signaling. NO can influence various signaling pathways, including those regulating protein modification, which might indirectly increase the activity of LOC728379 in the cell. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG132 is a proteasome inhibitor that can lead to the accumulation of ubiquitinated proteins, which may enhance the demand for deubiquitinating enzymes like LOC728379, potentially increasing its activity by substrate availability. | ||||||
Okadaic Acid | 78111-17-8 | sc-3513 sc-3513A sc-3513B | 25 µg 100 µg 1 mg | $291.00 $530.00 $1800.00 | 78 | |
Okadaic acid is a potent inhibitor of protein phosphatases PP1 and PP2A, leading to increased phosphorylation levels within the cell. This can indirectly enhance LOC728379 activity by influencing the phosphorylation state of proteins that interact with LOC728379. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
Thapsigargin inhibits the sarco/endoplasmic reticulum Ca2+-ATPase (SERCA), leading to a rise in cytosolic calcium levels. This can indirectly activate LOC728379 by influencing calcium-dependent protease activities and protein interactions. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a broad-spectrum protein kinase inhibitor that might lead to the selective activation of LOC728379 pathways by modifying the phosphorylation state of proteins within LOC728379-related processes. | ||||||